Bridgefront Capital’s ResMed RMD Stock Holding History

Bridgefront Capital’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,469	Closed	-$597K	–	532
2023 Q4	$597K	Buy	+3,469	New	+$533K	0.45%	54
2023 Q3	–	Sell	-4,123	Closed	-$901K	–	574
2023 Q2	$901K	Buy	+4,123	New	+$919K	0.49%	32
2023 Q1	–	Sell	-2,051	Closed	-$427K	–	559
2022 Q4	$427K	Buy	+2,051	New	+$451K	0.3%	127
2022 Q3	–	Sell	-2,096	Closed	-$439K	–	442
2022 Q2	$439K	Buy	+2,096	New	+$446K	0.49%	52
2021 Q2	–	Sell	-1,347	Closed	-$261K	–	861
2021 Q1	$261K	Buy	+1,347	New	+$270K	0.08%	478

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgefront Capital's RMD Position: Q1 2024 in Review

Bridgefront Capital sold out of ResMed (RMD) in Q1 2024, closing a stake of 3,469 shares — an estimated $597K sold.

Bridgefront Capital first reported a position in RMD in Q1 2021 and held it in 5 quarters. The position peaked at $901K in Q2 2023. 718 funds tracked by Wall St. Rank hold RMD as of Q1 2024.

Bridgefront Capital reported no remaining ResMed position as of Q1 2024 after selling out during the quarter.
Bridgefront Capital sold 3,469 ResMed shares in Q1 2024, an estimated $597K.
Bridgefront Capital first reported a position in ResMed in Q1 2021 and held it in 5 quarters.
Bridgefront Capital's ResMed position peaked at $901K in Q2 2023.
718 funds tracked by Wall St. Rank held ResMed as of Q1 2024.

Based on Bridgefront Capital's 13F filing for Q1 2024, filed 15 May 2024.